Literature DB >> 10229912

Iodide symporter gene expression in normal and transformed rat thyroid cells.

F Trapasso1, R Iuliano, E Chiefari, F Arturi, A Stella, S Filetti, A Fusco, D Russo.   

Abstract

OBJECTIVE: Decrease or loss of the Na+/I- symporter (NIS) activity profoundly affects the suitability of the use of radioiodine to detect or treat metastatic thyroid tissues. The aim of our study was to verify whether specific oncogene abnormalities were responsible for the alteration in NIS activity in thyroid cells. DESIGN AND METHODS: Expression of the NIS gene was investigated by Northern blot analysis in normal and in some oncogene-transformed cell lines with different degrees of malignancy which had lost the iodide uptake ability.
RESULTS: NIS gene expression was up-regulated by TSH in a dose-dependent and time-dependent way in normal PC Cl 3 cells. The same effect was observed by activating the cAMP-dependent pathway by forskolin. Conversely, insulin and 12-O-tetradecanoylphorbol-13-acetate (TPA) showed a partial inhibitory effect on NIS gene expression. The oncogene-transformed cell lines PC v-erbA, PC HaMSV, PC v-raf, and PC E1A cells showed reduced NIS mRNA levels compared with the normal PC Cl 3 cells. Conversely, an almost complete absence of NIS gene expression was found in PC RET/PTC, PC KiMSV, PC p53(143ala), and PC PyMLV cell lines.
CONCLUSIONS: Our data show that oncogene activation could play a role in affecting the iodide uptake ability in thyroid tumoral cells; different mechanisms are involved in the oncogene-dependent loss of NIS activity in transformed thyroid cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10229912     DOI: 10.1530/eje.0.1400447

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  15 in total

Review 1.  Regulation of sodium/iodide symporter.

Authors:  S M Jhiang
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

Review 2.  The biology of the sodium iodide symporter and its potential for targeted gene delivery.

Authors:  Mohan Hingorani; Christine Spitzweg; Georges Vassaux; Kate Newbold; Alan Melcher; Hardev Pandha; Richard Vile; Kevin Harrington
Journal:  Curr Cancer Drug Targets       Date:  2010-03       Impact factor: 3.428

3.  Efficient multicistronic co-expression of hNIS and hTPO in prostate cancer cells for nonthyroidal tumor radioiodine therapy.

Authors:  Guoquan Li; Lei Xiang; Weidong Yang; Zhe Wang; Jing Wang; Kai Chen
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-10-15

Review 4.  Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine.

Authors:  Stefania Bulotta; Marilena Celano; Giuseppe Costante; Diego Russo
Journal:  Endocrine       Date:  2015-12-21       Impact factor: 3.633

5.  PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells.

Authors:  Marialuisa Sponziello; Antonella Verrienti; Francesca Rosignolo; Roberta Francesca De Rose; Valeria Pecce; Valentina Maggisano; Cosimo Durante; Stefania Bulotta; Giuseppe Damante; Laura Giacomelli; Cira Rosaria Tiziana Di Gioia; Sebastiano Filetti; Diego Russo; Marilena Celano
Journal:  Endocrine       Date:  2015-04-03       Impact factor: 3.633

6.  Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer.

Authors:  M Huang; R K Batra; T Kogai; Y Q Lin; J M Hershman; A Lichtenstein; S Sharma; L X Zhu; G A Brent; S M Dubinett
Journal:  Cancer Gene Ther       Date:  2001-08       Impact factor: 5.987

7.  Nucleophosmin delocalization in thyroid tumour cells.

Authors:  Annalisa Pianta; Cinzia Puppin; Nadia Passon; Alessandra Franzoni; Milena Romanello; Gianluca Tell; Carla Di Loreto; Stefania Bulotta; Diego Russo; Giuseppe Damante
Journal:  Endocr Pathol       Date:  2011-03       Impact factor: 3.943

8.  Relationship of sodium/iodide symporter expression with I131 whole body scan uptake between primary and metastatic lymph node papillary thyroid carcinomas.

Authors:  S J Lee; K-C Choi; J P Han; Y-E Park; M G Choi
Journal:  J Endocrinol Invest       Date:  2007-01       Impact factor: 4.256

Review 9.  The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics.

Authors:  Takahiko Kogai; Gregory A Brent
Journal:  Pharmacol Ther       Date:  2012-06-29       Impact factor: 12.310

Review 10.  Thyroid Carcinoma: Phenotypic Features, Underlying Biology and Potential Relevance for Targeting Therapy.

Authors:  Jinwei Hu; Isabella J Yuan; Saied Mirshahidi; Alfred Simental; Steve C Lee; Xiangpeng Yuan
Journal:  Int J Mol Sci       Date:  2021-02-16       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.